VVM
KYTH

Versant Venture Management’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Versant Venture Management’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-70,376
Closed -$3.53M – 7
2015
Q1 		$3.53M Hold
70,376
– – 3.1% 6
2014
Q4 		$2.44M Buy
+70,376
New +$2.46M 2.33% 5

Other funds holding KYTH

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Versant Venture Management's KYTH Position: Q2 2015 in Review

Versant Venture Management sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q2 2015, closing a stake of 70,376 shares — an estimated $3.53M sold.

Versant Venture Management first reported a position in KYTH in Q4 2014 and held it in 2 quarters. The position peaked at $3.53M in Q1 2015. 153 funds tracked by Wall St. Rank hold KYTH as of Q2 2015.

  • Versant Venture Management reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q2 2015 after selling out during the quarter.
  • Versant Venture Management sold 70,376 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q2 2015, an estimated $3.53M.
  • Versant Venture Management first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q4 2014 and held it in 2 quarters.
  • Versant Venture Management's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $3.53M in Q1 2015.
  • 153 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q2 2015.

Based on Versant Venture Management's 13F filing for Q2 2015, filed 15 Jul 2015.